Merck Exits Insulin Glargine Market, Remains Committed to Biosimilars
Total Page:16
File Type:pdf, Size:1020Kb
19 October 2018 No. 3927 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa The follow-on product, developed with partner Samsung Bioepis Co. Ltd., would have been the third Lantus version on the market in the US behind Sanofi’s original product and Eli Lilly & Co.’s Basaglar, which launched in December 2015 after Lilly reached a patent settlement agreement with Sanofi. Both copies are technically approved under the 505(b)(2) regulatory pathway for NDAs, rather than through the biosimilar pathway, based on the way insulin is cate- gorized at the FDA, but the agency is recat- egorizing insulins as biologics in a transition that will go into effect in 2020. ANOTHER SETBACK FOR BIOSIMILARS? Merck’s decision could be another sign that the US biosimilar market isn’t living up to the early hype. A handful of initial lackluster Merck Exits Insulin Glargine Market, launches have raised questions about the commercial potential for biosimilars in the US in the near-term. Even FDA Commis- Remains Committed To Biosimilars sioner Scott Gottlieb has expressed concern JESSICA MERRILL [email protected] that slow launches could lead drug manu- facturers to curtail biosimilar R&D. (Also see erck & Co. Inc. has decided that The decision is surprising since the prod- “FDA’s Gottlieb: ‘Pricing And Reimbursement it will not commercialize its own uct was tentatively approved by the FDA in Mischief’ Holding Back Biosimilar Market” - Mversion of Sanofi’s Lantus (insulin July 2017, though it had not launched. Ten- Scrip, 7 Mar, 2018.) glargine) in the US, even though the prod- tative approval is used by the FDA when a Momenta announced Oct. 1 that it is uct was already tentatively approved by the drug is permitted to enter the market pend- exiting most biosimilar development to US FDA in 2017. ing the resolution of ongoing patent litiga- focus on a novel pipeline of drugs after a “After a comprehensive assessment of tion. Sanofi filed a patent infringement suit lengthy strategic review under which it the current and future market environ- against Merck in August 2017, triggering a failed to find a buyer for the business. CEO ment for insulin glargine, which included 30-month stay of action. Craig Wheeler said the patent delays and an assessment of anticipated pricing and Merck is already a strong player in the market uncertainty partly contributed to cost of production, we made the business diabetes market with the blockbuster the decision. Merck is one of just a few drug makers decision to terminate our agreement on Januvia (sitagliptin), so the company that has experienced the challenging US the commercialization of Lusduna pen would presumably already have the com- biosimilar market first-hand. The company’s and vial,” Merck said in a statement to Scrip. mercial structure in place to market an Renflexis (infliximab-abda) was the second The firm said it will reallocate resources in- insulin copy. However, the insulin market biosimilar version of Johnson & Johnson’s cluding commercial and manufacturing has become highly competitive with dif- capacity to other products. ficult dynamics. CONTINUED ON PAGE 4 BROUGHT TO YOU BY THE EDITORS OF PHARMASIA NEWS, START-UP AND SCRIP INTELLIGENCE Drug Price Increases China Vs Cancer BMS’s Checkmate-331 Failure Never say never, says Regeneron (p8) Reimbursement for 17 cancer Analysts predict Opdivo will drugs, but pricing pressures (p10) keep SCLC indication (p12) IN THIS ISSUE from the editor [email protected] Another week, another exit in biosimilars. Last week bears witness to the enthusiasm for the European bio- we reported on Momenta’s decision to get out of the similar market (see p5). biosimilars game; this week it is Merck & Co that has October 16 was a particularly noteworthy watershed decided not to enter the US market for insulin glargine moment for the EU market, as it marked the date at despite having a product with tentative FDA approval which the first biosimilar versions of AbbVie’sHumira (see cover story). While this decision may reflect specific (adalimumab) were permitted to launch there (see p4). challenges in the insulin market and Merck’s own cir- It’s the third anti-TNF blockbuster to fall to the copycats, cumstances, it comes against a wider backdrop of un- after Remicade (infliximab) andEnbrel (etanercept), but it’s certainty over the viability of the biosimilars space for the biggest prize of all. Global Humira sales, at $18.9bn in market entrants given the effectiveness of originator 2017 including those booked by Eisai in Japan, are more company defense tactics. than double those of of Remicade ($7.2bn) and Enbrel In contrast to the thicket of challenges with which ($7.9bn). With four heavyweight entrants now ready to biosimilar companies are contending in the US, Eu- hit the ground running with biosimilar adalimumab, this rope is a garden of delights. Mundipharma’s acquisi- is a key moment of truth for AbbVie. Will it really be able tion of Spanish biosimilar developer Cinfa Biotech to limit ex-US erosion to 20%? LEADERSHIP ADVERTISING DESIGN Phil Jarvis, Mike Ward, Christopher Keeling Paul Wilkinson Karen Coleman DESIGN SUPERVISOR SUBSCRIPTIONS Gayle Rembold Furbert Scrip Dan Simmons, Ewan Ritchie, Shinbo Hidenaga EDITORS IN CHIEF Andrea Charles EDITORIAL OFFICE Ian Haydock (Asia) John Davis Christchurch Court Eleanor Malone (Europe) Kevin Grogan 10-15 Newgate Street Denise Peterson (US) Ian Schofield London, EC1A 7AZ Vibha Sharma CUSTOMER SERVICES Joanne Shorthouse EXECUTIVE EDITORS US Toll-Free: +1 888 670 8900 COMMERCIAL Sten Stovall US Toll: +1 908 547 2200 Alexandra Shimmings (Europe) UK & Europe: +44 (20) 337 73737 Mary Jo Laffler (US) US Australia: +61 2 8705 6907 Michael Cipriano POLICY AND REGULATORY Japan: +81 3 6273 4260 Derrick Gingery Maureen Kenny (Europe) Email: clientservices@ Joseph Haas Nielsen Hobbs (US) pharma.informa.com Emily Hayes ASIA Mandy Jackson Cathy Kelly TO SUBSCRIBE, VISIT Anju Ghangurde scrip.pharmaintelligence.informa.com Jung Won Shin Jessica Merrill TO ADVERTISE, CONTACT Brian Yang Brenda Sandburg Bridget Silverman [email protected] Sue Sutter EUROPE All stock images in this publication Neena Brizmohun courtesy of www.shutterstock.com Francesca Bruce unless otherwise stated Scrip is published by Informa UK Limited. ©Informa UK Ltd 2018: All rights reserved. ISSN 0143 7690. 2 | Scrip | 19 October 2018 © Informa UK Ltd 2018 Mylan’s Chrys Kokino Humira patent litigation20 4 Evobrutinib partner search 14 21 exclusive online content inside: COVER / Merck Exits Insulin Glargine Market, Celgene’s Positive Phase III Data For Otezla In Scalp Remains Committed To Biosimilars Psoriasis Could Yield Broader Label https://bit.ly/2NNyjHE 4 Sandoz And AbbVie Humira Settlement: What Does It Mean? Celgene estimates 80% of moderate-to-severe plaque psoriasis patients experience the disease in their scalps, meaning positive 5 Mundipharma Satisfies Appetite For Piece Of $4.5bn data in this indication could broaden the market opportunity Pegfilgrastim Pie With Cinfa Biotech Buy for Otezla substantially. Novartis’ Cosentyx got scalp psoriasis added to its US label in February. 6 US Drug Pricing Challenges Poised To Impact Pharma Growth, Leerink Warns Hemophilia Seen As Good Testing Ground For 7 Infographic Commercializing Gene Therapy https://bit.ly/2NMvwye 8 We Haven’t Ruled Out Drug Price Increases, With a well characterized genetic driver, a clear marker to show Says Regeneron’s Schleifer whether it’s working, and available treatments that carry high annual costs, hemophilia may be a good testing ground for 10 China Vs. Cancer: Coverage For 17 Drugs Unveils Price commercializing gene therapy, but payers still have to work out Pressures, Commercial Battleground how to reimburse the one-time medicines. 11 Key Cancer Data To Be Unveiled At ESMO In Munich Gotham Therapeutics Raises $54M Series A To Target RNA-Modifying Proteins 12 Bristol’s Checkmate-331 Failure Not Likely To Endanger https://bit.ly/2AeepCa SCLC Labeling For Opdivo Versant Ventures seed company Gotham Therapeutics emerges from stealth mode to develop novel class of drugs targeting 13 Carrick Targets Ovarian Cancer With BTG Deal, RNA-modifying proteins with backing from co-leads Versant, Entices Celgene’s Former Top Deal Maker Forbion and SR One. 14 Merck of Germany’s Hunt For MS BTKi Partner Boosted By Evobrutinib Data Can Lilly’s Olumiant Prickle Xeljanz In India? https://bit.ly/2RWdrRS 18 Akcea Expects Convenience Edge For Tegsedi, Lilly’s Olumiant has hit the Indian market, upping the level Despite Monitoring Requirements of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at 20 Ionis Catches The Eye With New Roche Alliance least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake? 21 Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars Finance Watch: VC Tally Hits $14.5bn For 2018, Beating 2017 With A Quarter Left To Go 22 Pipeline Watch https://bit.ly/2RYmz8i US VC investment in biopharma totaled $14.5bn in the first 23 Appointments three quarters of 2018, exceeding the full-year 2017 sum of $11.9bn. UK biotech cash also is rising, benefitting new companies like Sitryx. @PharmaScrip /scripintelligence /scripintelligence /scripintelligence scrip.pharmaintelligence.informa.com 19 October 2018 | Scrip | 3 HEADLINE NEWS/HUMIRA SETTLEMENT CONTINUED FROM COVER Remicade (inifliximab) to launch in July 2017, behind Pfizer Inc.’s Inflectra (inflix- Sandoz And AbbVie Humira imab-dyyb). Renflexis launched at a discount to Settlement: What Does It Mean? the list prices of both other infliximabs ELEANOR MALONE & KEVIN GROGAN but failed to gain traction in the market. Branded Remicade has maintained a 94% share of the infliximab market two years after the first biosimilar launch, largely because of J&J’s successful defensive contracting strategy.